Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology
-$0.26 today
- Market cap
- $775.03M
- Beta
- 1.60
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.98
Volume 1.26M
Average 1.02M
GLUE Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Monte Rosa Therapeutics, Inc.NASDAQ: GLUE
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 33.3% from a year ago
Common stock stood at $8K at the end of Q1 FY2026, up 33.3% from a year earlier and up 14.3% from the prior quarter. Over 3 fiscal years it compounded at +11.9% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +33.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 7K USD
- Year-over-year change
- +16.7%
- 4-year CAGR
- +8.8%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7K | +16.7% |
| FY2024 | 2024-12-31 | 6K | +20.0% |
| FY2023 | 2023-12-31 | 5K | +0.0% |
| FY2022 | 2022-12-31 | 5K | +0.0% |
| FY2021 | 2021-12-31 | 5K | — |
Common Stock vs competitors
How GLUE compares with its peers on the latest reported figures
- GLUE's Mar 2026 common stock of $8K is the lowest of the 4 companies compared; the peer median is $100K.
- Its year-over-year change of +33.3% is the 3rd highest of 4, against a peer median of +41.6%.
- Common stock amounts to 0.0% of total assets for GLUE, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $109K | +41.6% | +29.5% | 0.0% | |
| Mar 2026 | $100K | +0.0% | — | 0.0% | |
| Mar 2026 | $10K | +42.9% | +21.6% | 0.0% | |
| Mar 2026 | $8K | +33.3% | +11.9% | 0.0% | |
| Peer median (excluding GLUE) | $100K | +41.6% | +25.6% | 0.0% | |
Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 346.07M | 54.91M | 128.1M | 224.25M | 129.88M |
| Short-term Investments | 0 | 207.91M | 104.31M | 147.9M | 247.22M |
| Net Receivables | 0 | 7.66M | 505K | 173K | 4.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.4M | 3.29M | 5.12M | 11.48M |
| Total Current Assets | 348.67M | 275.89M | 236.21M | 377.44M | 393.19M |
| Property, Plant & Equipment (Net) | 12.33M | 61.91M | 62.61M | 56.31M | 50.37M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 5.34M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 4.6M | 4.93M | 4.98M | 5.1M |
| Total Non-current Assets | 17.66M | 66.5M | 67.54M | 61.29M | 55.47M |
| Total Assets | 366.33M | 342.39M | 303.76M | 438.73M | 448.66M |
| Account Payables | 6.56M | 7.86M | 11.15M | 17.22M | 3.55M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 17.68M | 117.23M | 29.57M |
| Other Current Liabilities | 840K | 10.64M | 9.26M | 11.57M | 11.58M |
| Total Current Liabilities | 16.64M | 25.57M | 46.59M | 156.95M | 64.21M |
| Long-term Debt | 0 | 0 | 0 | 0 | 34.79M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 32.32M | 16.15M | 111.33M |
| Other Non-current Liabilities | 2.18M | 1.53M | 2.71M | 3.7M | 5.27M |
| Total Non-current Liabilities | 2.18M | 45.41M | 77.91M | 58.85M | 151.39M |
| Total Liabilities | 18.81M | 70.98M | 124.51M | 215.8M | 215.6M |
| Common Stock | 5K | 5K | 5K | 6K | 7K |
| Retained Earnings | (122.04M) | (230.54M) | (365.89M) | (438.59M) | (477.21M) |
| Accumulated OCI | (2.02M) | (1.75M) | (2.72M) | (3.36M) | (3.83M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 347.52M | 271.41M | 179.25M | 222.94M | 233.06M |
| Total Debt | 0 | 47M | 46.04M | 42.72M | 39.19M |
| Net Debt | (346.07M) | (7.91M) | (82.06M) | (181.54M) | (90.69M) |
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
Intrinsic Alpha fair value
Locked
Current Price
$9.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.